Connect your AI

CG Oncology CGON Stock-Based Comp

Stock-Based Comp at other companies

PfizerPFE

$272M+60.0%

Johnson & JohnsonJNJ

$300M+4.2%

Gilead SciencesGILD

$218M+4.3%

ImmunityBio, Inc.IBRX

$8.17M-14.3%

Cogent Biosciences, Inc.COGT

$16.91M+68.9%

Tango TherapeuticsTNGX

$10.8M+48.8%

Other financials

Income statement

Revenue$1.1M+1,983%

Operating income-$66.4M-57.3%

Net income-$60.2M-74.7%

EPS (diluted)-$0.71-57.8%

Balance sheet

Cash & equivalents$33.7M-18.7%

Total debt$7.6M+631%

Total equity$1.1B+54.9%

Total assets$1.1B+55.9%

Cash flow

Operating cash flow-$56.9M-94.5%

CapEx$304.0K+1,800%

Free cash flow-$57.2M-95.4%

Valuation

Market cap$5.39B+206%

Profitability

Operating margin-4,239%-1,872pp

Net margin-3,682.6%-1,601pp

FCF margin-3,163.8%-1,351pp

Returns & leverage

Return on equity-20.8%+7.1pp

Debt / equity0×0.0×

Current ratio31.3×+0.3×

Where this comes from

Reported directly by CG Oncology in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: CG Oncology’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about CG Oncology's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is CG Oncology's stock-based comp?: CG Oncology (CGON) reported stock-based comp of $6.47M in Q1 2026.
How has CG Oncology's stock-based comp changed year-over-year?: CG Oncology's stock-based comp increased by 25.7% year-over-year, from $5.15M to $6.47M.
What is the long-term trend for CG Oncology's stock-based comp?: Over 2 years (2023 to 2025), CG Oncology's stock-based comp has grown at a 317.8% compound annual growth rate (CAGR), from $1.53M to $26.68M.
What does stock-based comp mean?: Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.